Business Wire

NEUSTAR

14.8.2019 09:02:04 CEST | Business Wire | Press release

Share
Neustar: ‘Under the Radar’ DDoS Attacks Increase by 158 Percent in Q2, 2019 Compared to the Same Time Last Year

Small-scale Distributed Denial of Service (DDoS) attacks are becoming more frequent and sophisticated, according to new research from Neustar ’s Security Operations Centre (SOC). Released today, the Q2, 2019 Cyber Threats and Trends report reveals that between April and June of this year, over 75 percent of all attacks mitigated by Neustar were 5 Gigabits per second (Gbps) or less, while large attacks – those of 100 Gbps and over – decreased by 64 percent.

At first glance, the evolution of DDoS attacks on enterprises seems to follow a pattern. The overall number of attacks during Q2 2019 compared with the previous year grew by 133 percent, which, though down from last quarter’s 200% growth, is still high. Stepping outside an analysis of the numbers of attacks to their composition, however, shows some interesting changes, according to Neustar.

Small and secretive

DDoS attacks have long been considered overwhelming threats and are traditionally associated with high rates of traffic. Such attacks do continue to take place, but smaller and more carefully targeted incursions are growing in quantity, intensity and duration. Such attacks do not seek to saturate the network link – and draw unwanted attention in the process – but to degrade or disable specific infrastructure within the target. Such lower volume incursions may enable the perpetrator to get in and get out unnoticed, or allow the attack to continue for quite a long time undetected. In fact, the longest duration for a single attack in Q2 was nearly two days.

These small attacks pose a significant threat, as they fall below the typical threshold that enterprises with a “detect and alert” DDoS mitigation strategy might employ. An attacker could therefore affect targets ranging from infrastructure to individual servers with relative impunity.

The situation becomes more alarming when considering an enterprise’s ability to recognise such threats when they were underway. When asked how likely they would be to notice today’s most prevalent smaller attacks, a staggering 72 percent of CTOs, CISOs and Directors of Security from the Neustar International Security Council (NISC) answered very unlikely, somewhat unlikely or somewhat likely. The remaining 28 percent of respondents felt it was very likely that they would notice a small-scale DDoS attack.

“With the rise of smaller DDoS attacks going under the radar, now is the time for organisations to deploy an ‘always on’ DDoS mitigation service that is constantly monitoring traffic to ensure threats of all sizes are detected, managed and diffused,” said Rodney Joffe, Senior Vice President, Senior Technologist and Fellow at Neustar.

“Now, with most of today’s attacks directed at specific services, gateways and applications – therefore requiring less traffic to bring it down – a greater level of understanding from businesses to determine the protection they need is essential. The first stage of this is to determine what is valuable, not what is vulnerable. One of the best ways to separate vulnerability from value is to create a ‘risk register’ that starts from the inside and focuses on your most critical business assets,” Joffe added.

A complimentary copy of The Neustar Q2’19 Cyber Threats and Trends Report is available here .

- ENDS -

About Neustar, Inc.

Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye